A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
about
Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severityA cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.Palivizumab compliance by infants in Puerto Rico during the 2009-2010 respiratory syncytial virus season.Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis.Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody.The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists.Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populationsClinical Decision Support and Palivizumab: A Means to Protect from Respiratory Syncytial VirusReview of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The NetherlandsAdherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States countiesManaging the morbidity associated with respiratory viral infections in children with congenital heart diseaseProduct review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Respiratory syncytial virus prevention in children with congenital heart disease: who and how?Increased risk of RSV infection in children with Down's syndrome: clinical implementation of prophylaxis in the European Union.Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic
P2860
Q27010165-1BDAEECC-B3F3-4F43-AFA5-7EF4BE8FDDADQ30393843-E0C821D4-A183-4A89-A0F3-C939AA81DBA3Q33723350-3853B278-4B46-4E3A-B8BC-6942A45521D3Q34446682-9EAC3D76-D7A9-437D-83FF-B8E0C6A44F3CQ34839654-702554A2-4F61-4DEC-9D7C-FFE1E5C42053Q34875961-F8CC8668-33D2-4BB3-A7EA-6EFE24AA1906Q35018061-1363B94F-20CF-415A-B7A9-938D0C5A74DAQ35888993-733401C4-B15D-4A8E-B196-20CA20B4107EQ35892685-A86F7C5C-8828-40C5-BCE4-BC83380E2248Q36438581-332697AE-459E-4B6D-A2F5-722B9FDE9EF9Q36582250-802EE854-BB30-4FC7-AFA1-6A2527CDCE60Q37173318-A56EB368-6427-48F1-B014-787480452BAFQ38003985-ADF7B689-84F1-4910-B625-7AC72FC19E94Q38671952-A6EF5A72-AEBC-471C-AF7F-3DC3CA9B9E6DQ39719279-77129DA5-EA70-4134-B15C-E54E5B9587DAQ42226322-472C2388-F4C1-4372-80D5-CF08473E661EQ42376924-8C9DEB95-F114-4D9C-ABE0-C2AD99F9A103
P2860
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic review of complia ...... ion for RSV immunoprophylaxis.
@en
A systematic review of complia ...... ion for RSV immunoprophylaxis.
@nl
type
label
A systematic review of complia ...... ion for RSV immunoprophylaxis.
@en
A systematic review of complia ...... ion for RSV immunoprophylaxis.
@nl
prefLabel
A systematic review of complia ...... ion for RSV immunoprophylaxis.
@en
A systematic review of complia ...... ion for RSV immunoprophylaxis.
@nl
P2093
P1476
A systematic review of complia ...... ion for RSV immunoprophylaxis.
@en
P2093
Ancilla W Fernandes
Dan L Stewart
Michael Hoopes
Michael P Frogel
Parthiv J Mahadevia
P356
10.18553/JMCP.2010.16.1.46
P577
2010-01-01T00:00:00Z